Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients

Nonalcoholic fatty liver disease (NAFLD) refers to excess fat accumulation in the liver. In animal experiments and human kinetic study, we found that administration of combined metabolic activators (CMAs) promotes the oxidation of fat, attenuates the resulting oxidative stress, activates mitochondri...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeybel, Mujdat, Altay, Ozlem, Arif, Muhammad, Li, Xiangyu, Yang, Hong, Fredolini, Claudia, Akyildiz, Murat, Saglam, Burcin, Gonenli, Mehmet Gokhan, Ural, Dilek, Kim, Woonghee, Schwenk, Jochen M, Zhang, Cheng, Shoaie, Saeed, Nielsen, Jens, Uhlén, Mathias, Borén, Jan, Mardinoglu, Adil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724764/
https://www.ncbi.nlm.nih.gov/pubmed/34694070
http://dx.doi.org/10.15252/msb.202110459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724764/
https://www.ncbi.nlm.nih.gov/pubmed/34694070
http://dx.doi.org/10.15252/msb.202110459

Ejemplares similares